Gapping down In reaction to disappointing earnings/guidance: DF -8.3%, DVR -7.2%, EVEP -2.4%, GOGO -1.7%, PCLN -1.4%, AU -1.2%, SSL -0.8%, TECH -0.5%.
M&A news: RDS.A -0.5% (Blackstone (BX) near deal for 50% Shell (RDS.A) Haynesville shale, according to reports).
Select EU financial related names showing weakness: RBS -2.4% (to sell international unit of private bank, according to reports), DB -1.5%, HSBC -1% (to keep private bank, according to reports), SAN -0.8%, CS -0.7%.
Other news: VRTV -5% (Baupost Group discloses 14.06% passive stake in 13G filing), Z -2% (ticking lower following cautious Barron's mention), ARMH -1.4% (still checking).
Analyst comments: TWOU -8.7% (downgraded to Neutral from Buy at Goldman), CEQP -1% (downgraded to Market Perform from Outperform at Wells Fargo), TDW -0.9% (downgraded to Accumulate from Buy at Global Hunter Securities), THOR -0.6% (downgraded to Market Perform from Outperform at Northland ), KING -0.4% (downgraded to Sector Perform from Outperform at Pacific Crest).
Gapping up In reaction to strong earnings/guidance: WBAI +6.4%, TTM +5.8%, MFRM +5.1%, RGEN +4.1%, ARMK +3.5%, BITA +2.8%, MPAA +2.3%, USEG +2.3%, HE +1.6%, TSM +0.8%, ADHD +0.6%, ZOES +0.5%.
M&A news: KMI +20.1% (to purchase KMP, KMR and EPB; 2015 KMI dividend to increase to $2 per share), KMR +34.6%, EPB +30.5%, KMP +27.1%.
Other news: PIP +42.9% (Delaware Court of Chancery orders SIGA to pay PharmAthene lump sum expectation damages), DRL +28% (disclosed settlement with the Treasury Department), MNKD +25% (SNY and MannKind announce global licensing agreement for Afrezza rapid-acting inhaled insulin), HGSH +21.5% (will be engaged in large-scale Shanty Areas rebuilding Projects with budgeted investment over $1.3 billion), BIOD +10.5% (concentrated Insulin BIOD-531 demonstrates superior glucose control following standardized meals vs marketed insulins in a Phase 2 Clinical Trial in patients with Type 2 Diabetes), TKMR +7.2% (continued momentum on ebola exposure), BCRX +5.9% (may be related to MNKD news, biotech peer), OXGN +5.7% (maybe related to MNKD news, biotech peer), KNDI +3.6% (may be related to TSLA upgrade, also Shanghai strong overnight), NQ +2.5% (cont volatility), PLUG +2.3% (continued momentum), BYI +2.3% (may be related to acquisition in the space), JD +2.3% (Shanghai strong overnight), MY +2.2% (stong Shanghai overnight), RIO +1.8% (strong Chinese markets overnight), NOK +1.6% (launches new MSFT phone), HLF +1.5% (Capital Research Global Investors discloses 10.1% passive stake in 13G filing), JKS +1.3% (opens solar module factory in Cape Town, South Africa), CCL +1.2% (cruised data released Friday), PVG +0.9% (provides Q2 updates on Brucejack Project; increases in Valley of the Kings mineral grade).
Analyst comments: ACHN +8% (upgraded to Outperform from Market Perform at Wells Fargo, upgraded to Overweight from Neutral at Piper Jaffray), KKD +4.6% (upgraded to Outperform from Neutral at Wedbush), CDNA +4.3% (initiated with a Buy at Mizuho, initiated with a Outperform at Leerink Partners), TSLA +2.7% (upgraded to Buy from Hold at Deutsche Bank), CHUY +2.4% (upgraded to Outperform from Mkt Perform at Raymond James), OAS +2% (upgraded to Buy from Neutral at Sterne Agee), GNC +1.9% (upgraded to Outperform from Neutral at Credit Suisse ), FMS +1.3% (upgraded to Buy from Hold at Societe Generale ), SD +0.9% (upgraded to Reduce from Sell at KLR Group), FCX +0.8% (upgraded to Buy from Hold at Argus), NFLX +0.7% (target raised to $527 at Topeka Capital Markets)
- Co reported preliminary net sales and adjusted EPS for the second fiscal quarter ended July 29, 2014.
- Net sales for the second fiscal quarter increased 35.5% to $410 million (Capital IQ consensus $384 mln), reflecting comparable-store sales growth of 9.7% and the addition of new and acquired stores. The Company expects second fiscal quarter earnings per diluted share on a generally accepted accounting principles basis of $0.39 to $0.42, and EPS on a non-GAAP adjusted basis, excluding ERP system implementation costs, acquisition-related costs and impairment and severance charges, is expected to be between $0.58 and $0.61 per diluted share for the second fiscal quarter, Capital IQ consensus $0.49.
- Co raises FY14 revenue guidance to $1.545-1.585 mln (Capital IQ consensus $1.53 bln)
- Raises Adjusted FY14 EPS guidance to $2.03-2.13 (Capital IQ consensus $1.95)
- Co issues downside guidance for Q3, sees EPS of ($0.15) - ($0.05) vs. $0.26 Capital IQ Consensus Estimate.
- Dean Foods' share of U.S. fluid milk sales volume increased to 35.9% during the second quarter from 35.7% in the first quarter of 2014. The Company continues to make solid progress against its accelerated cost reduction agenda. Since announcing in the first quarter of 2013 its intention to close eight to twelve (10-15%) of its manufacturing facilities by mid-2014 the Company has closed twelve plants. Four of the twelve closures occurred in June and July of this year. As we move beyond our accelerated cost reduction agenda, we expect to return to our normal optimization activities.
- Guidance: "The balance of the year appears rocky, with a continued unpredictable and volatile dairy commodity environment. That makes it difficult to provide guidance beyond the immediate quarter...Therefore for the time being, we are going to provide specific guidance only for the next quarter, where our visibility is better. In this case, we expect an adjusted diluted net loss of between $0.05 and $0.15 per share in the third quarter. While we hope to see a more positive environment later in the year, the uncertainty surrounding whether or when that will occur leads us to withdraw our full year guidance for the present time....We also expect to be at the low end of our prior 2014 capital expenditure guidance of $150-175 million."
Gapping down: SIGA -25.2%, ARMH -1.7%, DB -1.5%, PT -1.5%, Z -1.2%, CS -1%, HSBC -1%